OLUMIANT
FDA Accepts BLA for Anifrolumab by AstraZeneca
Pressure score
78
Momentum score
61
Why This Matters
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Approved
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Approved competitor status elevates immediate revenue and share risk.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA Accepts BLA for Anifrolumab by AstraZeneca
Immunology · Systemic Lupus Erythematosus · Regulatory Approval · This acceptance positions AstraZeneca to compete in the lupus market, potentially impacting existing therapies.
Source: Humanexa Signals
No public source document URL on file.
Related Signal
FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 3
Pfizer
2 competitive findings
Top program: OLUMIANT
- Pressure
- 82
- Momentum
- 64
- Threat
- regulatory competitor
- Stage
- Approved
82PfizerHighOLUMIANT·Approved
AstraZeneca
1 competitive finding
Top program: OLUMIANT
- Pressure
- 78
- Momentum
- 61
- Threat
- regulatory competitor
- Stage
- Approved
78AstraZenecaHighOLUMIANT·Approved
Roche
1 competitive finding
Top program: OLUMIANT
- Pressure
- 50
- Momentum
- 43
- Threat
- direct competitor
- Stage
- Approved
50RocheMediumOLUMIANT·Approved